Coeptis Therapeutics (NASDAQ:ZSQR – Get Free Report) and Next Technology (NASDAQ:NXTT – Get Free Report) are both small-cap technology companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, earnings, risk, profitability, analyst recommendations, institutional ownership and valuation.
Analyst Recommendations
This is a breakdown of current recommendations and price targets for Coeptis Therapeutics and Next Technology, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Coeptis Therapeutics | 1 | 0 | 0 | 0 | 1.00 |
| Next Technology | 1 | 0 | 0 | 0 | 1.00 |
Profitability
This table compares Coeptis Therapeutics and Next Technology’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Coeptis Therapeutics | -773.72% | -49.45% | -46.88% |
| Next Technology | -2,355.97% | -60.08% | -53.71% |
Volatility and Risk
Valuation and Earnings
This table compares Coeptis Therapeutics and Next Technology”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Coeptis Therapeutics | $1.36 million | 201.09 | -$11.92 million | ($1.63) | -3.17 |
| Next Technology | $11.61 million | 0.71 | $143.16 million | ($12,900.00) | -0.00 |
Next Technology has higher revenue and earnings than Coeptis Therapeutics. Coeptis Therapeutics is trading at a lower price-to-earnings ratio than Next Technology, indicating that it is currently the more affordable of the two stocks.
Institutional & Insider Ownership
13.9% of Coeptis Therapeutics shares are owned by institutional investors. Comparatively, 2.7% of Next Technology shares are owned by institutional investors. 24.2% of Coeptis Therapeutics shares are owned by company insiders. Comparatively, 52.2% of Next Technology shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Summary
Coeptis Therapeutics beats Next Technology on 6 of the 10 factors compared between the two stocks.
About Coeptis Therapeutics
Coeptis Therapeutics Holdings, Inc., a biopharmaceutical company, develops cell therapy platforms for patients with cancer. Its product portfolio consists of CD38-GEAR-NK, a cell therapy for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; SNAP-CAR, a CAR T cell therapy platform co-administered with tagged, tumor-specific antibodies to potentially target different tumor types, including hematological malignancies and solid tumors; and CD38-Diagnostic, an in vitro screening tool to analyze if cancer patients might be appropriate candidates for anti-CD38 mAb therapy. The company also offers its drugs for acute myeloid leukemia and acute respiratory diseases. Coeptis Therapeutics Holdings, Inc. has co-development agreement Vici Health Sciences, LLC to co-develop and share ownership rights to CPT60621 for the treatment of Parkinson's Disease. The company was founded in 2017 and is headquartered in Wexford, Pennsylvania.
About Next Technology
Next Technology Holding Inc. provides technical services and solutions through its social e-commerce platform primarily in Mainland China. It offers YCloud, a micro-business cloud intelligent internationalization system that conducts multi-channel data analysis through the learning of big data and social recommendation relationships, as well as provides users with AI fission and management systems, and supply chain systems. The company’s YCloud system also provides micro-business owners with various payment methods, such as Alipay, WeChat, and UnionPay. In addition, it offers chatGPT technical services; and technical system support, software development, and services. The company serves individual and corporate users in the micro business industry. It also has operations in Hong Kong and Singapore. The company was formerly known as WeTrade Group, Inc. and changed its name to Next Technology Holding Inc in April 2024. Next Technology Holding Inc. was incorporated in 2019 and is headquartered in Beijing, the People Republic of China.
Receive News & Ratings for Coeptis Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Coeptis Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
